July 5, 2017
U.S. Securities and Exchange Commission |
| |
Division of Corporation Finance |
| |
100 F Street, N.E. |
| |
Mail Stop 6010 |
| |
Washington, D.C. 20549-3628 |
| |
|
| |
Attn: | Dorrie Yale |
|
|
|
|
Re: | Akcea Therapeutics, Inc. |
|
| Registration Statement on Form S-1 |
|
| File No. 333-216949 |
|
| Withdrawal of Acceleration Request |
|
Ladies and Gentlemen:
Reference is made to our letter, filed as correspondence via EDGAR on June 27, 2017, in which we requested the acceleration of the effective date of the above-referenced registration statement for Thursday, June 29, 2017, at 4:30 p.m. Eastern Time, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such registration statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.
| Very truly yours, | |
|
| |
| Akcea Therapeutics, Inc. | |
|
| |
| By: | /s/ Patrick R. O’Neil |
|
| Patrick R. O’Neil |
|
| Corporate Secretary |
cc: | Paula Soteropoulos, Akcea Therapeutics, Inc. |
|
| Jeffrey M. Goldberg, Akcea Therapeutics, Inc. |
|
| Charles S. Kim, Cooley LLP |
|
| Nicole C. Brookshire, Cooley LLP |
|
| Sean Clayton, Cooley LLP |
|
| Richard C. Segal, Cooley LLP |
|
| Alan F. Denenberg, Davis Polk & Wardwell LLP |
|